CARDIOLOGY

Glucagon-Like Peptide-1 Receptor Agonists and Heart Failure Hospitalization in a Real-World Cardiometabolic Population

Aug 8, 2026 by in CARDIOLOGY Comments Off on Glucagon-Like Peptide-1 Receptor Agonists and Heart Failure Hospitalization in a Real-World Cardiometabolic Population
Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized as a cardiometabolic syndrome driven by obesity and related metabolic risk factors, yet strategies to prevent progression to clinically overt…
read more

Drug-Coated Balloon Versus Drug-Eluting Stent for Coronary Revascularization in Patients With Chronic Kidney Disease: A Real-World Propensity-Matched Study

Aug 8, 2026 by in CARDIOLOGY Comments Off on Drug-Coated Balloon Versus Drug-Eluting Stent for Coronary Revascularization in Patients With Chronic Kidney Disease: A Real-World Propensity-Matched Study
Chronic kidney disease (CKD) is associated with adverse outcomes after percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Drug-coated balloons (DCB) have emerged as a promising stentless alternative. This study…
read more

Comment on “The Effect of Vericiguat on Endothelial Function in Patients With Heart Failure With Reduced Ejection Fraction: A Pilot Randomized Study”

Aug 8, 2026 by in CARDIOLOGY Comments Off on Comment on “The Effect of Vericiguat on Endothelial Function in Patients With Heart Failure With Reduced Ejection Fraction: A Pilot Randomized Study”
We read with great interest the pilot randomized investigation by Sideris et al evaluating the vascular effects of vericiguat in heart failure with reduced ejection fraction. The study addresses an…
read more

Comment on “The Long-Term Clinical Progression of Genotype Positive/Phenotype Negative Patients With Hypertrophic Cardiomyopathy”

Aug 8, 2026 by in CARDIOLOGY Comments Off on Comment on “The Long-Term Clinical Progression of Genotype Positive/Phenotype Negative Patients With Hypertrophic Cardiomyopathy”
We read with interest the article by Puchnerova et al entitled “The Long-Term Clinical Progression of Genotype Positive/Phenotype Negative Patients with Hypertrophic Cardiomyopathy”, which provides serial clinical and imaging data…
read more

Three-Year Outcomes of Contemporary Left Main Coronary Intervention in Patients With and Without Acute Coronary Syndrome

Aug 8, 2026 by in CARDIOLOGY Comments Off on Three-Year Outcomes of Contemporary Left Main Coronary Intervention in Patients With and Without Acute Coronary Syndrome
We evaluated 3-year clinical outcomes after contemporary left main percutaneous coronary intervention in patients with and without acute coronary syndrome (ACS) in a real-world cohort, in which intracoronary imaging guidance…
read more

Clinical Differences and Disparities Among Men and Women With Acute Myocardial Infarction-Related Cardiogenic Shock Undergoing Percutaneous Coronary Intervention

Aug 8, 2026 by in CARDIOLOGY Comments Off on Clinical Differences and Disparities Among Men and Women With Acute Myocardial Infarction-Related Cardiogenic Shock Undergoing Percutaneous Coronary Intervention
There is limited sex-specific data on patients with acute myocardial infarction-related cardiogenic shock (AMI-CS), and little is known about the optimal management in female patients, including the impact of mechanical…
read more

Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study

Aug 8, 2026 by in CARDIOLOGY Comments Off on Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study
Tirzepatide has demonstrated cardiometabolic benefits in clinical trials, but real-world cardiovascular outcomes among patients without diabetes following acute cardiovascular events or stroke remain understudied. We evaluated clinical outcomes associated with…
read more

Impact of Cangrelor on Outcomes After Percutaneous Coronary Intervention for Acute Coronary Syndrome in High Bleeding Risk Patients

Aug 8, 2026 by in CARDIOLOGY Comments Off on Impact of Cangrelor on Outcomes After Percutaneous Coronary Intervention for Acute Coronary Syndrome in High Bleeding Risk Patients
Highlights • Cangrelor is a potent, intravenous, direct-acting P2Y12 receptor inhibitor. • Impact of cangrelor on outcomes in high bleeding risk (HBR) patients is unclear. • In our study, cangrelor…
read more
Get Clinical Tree app for offline access